Please assess the completion status of the following clinical trial:

Trial Title: A Study to Evaluate Rebif® New Formulation (Interferon-beta-1a) in Relapsing Remitting Multiple Sclerosis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: FACTORIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Males and females between 18 and 60 years of age~* Female subjects must be neither pregnant nor breast-feeding and must lack child-bearing potential, as defined by either: post-menopausal or surgically sterile or use an effective method of contraception for the duration of the study~* Have Relapsing Remitting Multiple Sclerosis (RRMS) according to the revised McDonald criteria 2005~* Have brain and/or spinal MRI with findings typical of Multiple Sclerosis (MS)~* Have disease duration for more than 12 months~* Have disease activity characterized by at least one clinical event and one or more Gadolinium-enhancing MRI lesions within the 6 months prior to randomization~* Have score of \<=5.5 on the Expanded Disability Status Scale (EDSS)~* Be willing and able to comply with the protocol for the duration of the study~* Have given written informed consent prior to any study-related procedure not part of the normal medical practice~Exclusion Criteria:~* Have any disease other than MS that could better explain his/her signs and symptoms~* Have complete transverse myelitis or bilateral optic neuritis~* Have received or have used anytime monoclonal antibodies, mitoxantrone, cytotoxic or immunosuppressive therapy (excluding systemic steroids and adrenocorticotrophic hormone \[ACTH\]), or total lymphoid irradiation~* Have received within 3 months prior to baseline any approved disease-modifying therapy for MS, cytokine or anti-cytokine therapy, intravenous immunoglobulin, plasmapheresis, any investigational drug, or experimental procedure~* Have received within 30 days prior to baseline oral or systemic corticosteroids or ACTH~* Other protocol defined exclusion criteria could apply

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Study Arms:
- Rebif® New Formulation (IFN-beta-1a, RNF) (Type: EXPERIMENTAL): None
- Placebo/RNF (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).